Celiac Panel: What Your Numbers Change About Your Treatment

What Is a Celiac Panel and What Does Each Marker Measure

A celiac panel is a blood test battery that uses your immune system's antibody response to gluten-related proteins as a diagnostic proxy for celiac disease. Ordering only a single marker misses a meaningful portion of cases, so most guidelines recommend a multi-marker approach combined with a total serum IgA level to catch the IgA-deficient subset of patients. American College of Gastroenterology (ACG) guidelines from 2023 specifically state: "We recommend serologic testing with a sensitive and specific test, tTG-IgA, be used for case finding and diagnosis of CD in patients with signs or symptoms suggestive of CD."

Tissue Transglutaminase IgA (tTG-IgA)

TTG-IgA is the first-line marker in virtually every national guideline. It detects IgA antibodies directed against the enzyme tissue transglutaminase 2, which modifies gliadin peptides in the intestinal mucosa. A 2019 systematic review in BMJ covering 119 studies found pooled sensitivity of 91.3% and specificity of 95.2% for tTG-IgA in adults. Results are reported as a ratio or numeric value against an assay-specific upper limit of normal (ULN). Most labs set the ULN between 4 and 20 U/mL depending on the platform used.

A result below the ULN is considered negative. A result between 1× and 3× ULN is weakly positive and warrants confirmatory EMA-IgA testing. A result at or above 10× ULN carries a positive predictive value exceeding 95% for villous atrophy on biopsy.

Anti-Endomysial Antibody IgA (EMA-IgA)

EMA-IgA has specificity approaching 98 to 99% but slightly lower sensitivity (around 86 to 90%) than tTG-IgA, making it ideal as a confirmatory rather than screening test. A Lancet study from Fasano et al. estimated the prevalence of celiac disease in the United States at 1 in 133 persons, and noted EMA positivity closely tracked mucosal damage severity. EMA-IgA is reported as a titer (negative, 1:5, 1:10, 1:40, 1:80). A positive titer at any level in the appropriate clinical context is significant.

Deamidated Gliadin Peptide Antibodies (DGP-IgA and DGP-IgG)

DGP antibodies are most useful in two scenarios. First, IgA-deficient patients cannot generate detectable tTG-IgA or EMA-IgA, so DGP-IgG becomes the primary screening marker for that group. Second, DGP antibodies tend to rise and fall faster than tTG-IgA after dietary change, giving them some utility as an early dietary adherence marker. A 2010 study in Alimentary Pharmacology and Therapeutics found DGP-IgG had sensitivity of 80.7% and specificity of 98.0% in IgA-deficient populations.

Total Serum IgA

Total serum IgA is not a celiac-specific marker, but ordering it alongside the rest of the panel is standard of care. Selective IgA deficiency affects roughly 1 in 400 to 1 in 600 people in the general population, and its prevalence among celiac patients may be 10 to 15 times higher than in the general public. A total IgA below 7 mg/dL invalidates any IgA-based celiac test result. The American Gastroenterological Association's 2023 clinical practice update confirms that total IgA should be measured concurrently with tTG-IgA in all patients undergoing celiac evaluation.

Normal Celiac Panel Range

"Normal" means antibody levels fall below each assay's upper limit of normal, combined with a total serum IgA in the adequate range. Reference intervals vary by laboratory platform.

Typical Reference Ranges by Marker

| Marker | Negative (Normal) | Weakly Positive | Strongly Positive | |---|---|---|---| | tTG-IgA | <4 U/mL (most platforms) | 4 to 40 U/mL (1 to 10× ULN) | >40 U/mL (>10× ULN) | | EMA-IgA | Negative titer | 1:5 or 1:10 | 1:40 or higher | | DGP-IgA | <20 U/mL (most platforms) | 20 to 100 U/mL | >100 U/mL | | DGP-IgG | <20 U/mL (most platforms) | 20 to 100 U/mL | >100 U/mL | | Total IgA | 70 to 400 mg/dL (adults) | 7 to 70 mg/dL (partial deficiency) | <7 mg/dL (invalidates IgA tests) |

These thresholds are approximate. Your lab's specific reference range, printed on your result report, takes precedence over any generic table. Results near the borderline deserve repeat testing or specialist review rather than a definitive interpretation in either direction.

Why the Same Number Can Mean Different Things

A tTG-IgA of 25 U/mL means something different in a patient with classic malabsorption symptoms, iron-deficiency anemia, and a first-degree relative with celiac disease versus a patient who had a borderline result on a wellness panel with no gastrointestinal symptoms. The USPSTF noted in its 2017 evidence review that routine screening of asymptomatic adults without known risk factors lacks sufficient evidence to recommend, precisely because the pre-test probability shapes how any given numeric result should be acted upon.

What a High Celiac Panel Result Means

A high result, defined as any marker above its ULN, requires clinical correlation with symptoms, history, and often small-bowel biopsy before a formal diagnosis of celiac disease is made. The height of the elevation directly changes the next step.

Mildly Elevated (1 to 3× ULN)

Mild elevations produce the most diagnostic uncertainty. A 2022 paper in Gastroenterology documented that only 30 to 40% of adults with tTG-IgA in the 1 to 3× ULN range had Marsh grade 3 villous atrophy on biopsy. The remainder showed either Marsh 1 or 2 changes (lymphocytic infiltration without atrophy) or normal mucosa. In this range, your clinician will typically confirm with EMA-IgA and refer for esophagogastroduodenoscopy (EGD) with duodenal biopsies rather than initiating a gluten-free diet based on serology alone.

Other conditions that can mildly raise tTG-IgA include type 1 diabetes mellitus, autoimmune thyroid disease (Hashimoto's thyroiditis, Graves' disease), inflammatory bowel disease, liver disease, and cardiac failure. This overlap is clinically important because celiac disease, Hashimoto's, and type 1 diabetes share HLA-DQ2 and HLA-DQ8 genetic risk alleles, leading to co-occurrence rates higher than chance alone would predict.

Markedly Elevated (≥10× ULN)

At this level the clinical picture changes. The European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) 2020 guidelines permit a biopsy-sparing diagnosis in children when tTG-IgA exceeds 10× ULN, EMA-IgA is confirmed positive, and the child carries HLA-DQ2 or DQ8. Adult guidelines from ACG 2023 have moved toward a similar position for highly symptomatic adults with tTG-IgA ≥10× ULN and positive EMA-IgA, though biopsy remains the standard for most adult cases in the United States.

A markedly elevated panel also means a higher burden of mucosal damage, which correlates with more severe nutrient deficiencies at the time of diagnosis and a longer recovery period on a gluten-free diet.

How High Results Affect Your Treatment Plan

When your panel is clearly positive and biopsy confirms Marsh 3 lesions, treatment is a strict, lifelong gluten-free diet. There are no approved pharmacologic alternatives for celiac disease as of January 2025. The diet must eliminate wheat, rye, barley, and any food cross-contaminated with those grains. Your clinician will also order a comprehensive nutrient screen covering serum ferritin, iron saturation, folate, vitamin B12, 25-hydroxyvitamin D, zinc, and copper, because untreated villous atrophy impairs absorption of all of these. Deficiencies found at diagnosis need targeted supplementation in addition to the dietary change.

What a Low or Negative Celiac Panel Result Means

A negative panel, meaning all markers below their ULN with an adequate total IgA, makes active celiac disease unlikely but does not rule it out in every situation.

When a Negative Result Is Reliable

In a patient eating a full gluten-containing diet with no selective IgA deficiency, a negative tTG-IgA has a negative predictive value above 97%, according to the 2019 BMJ systematic review cited above. For practical purposes, this means the test effectively rules out celiac disease in most people tested under the right conditions.

When a Negative Result Can Be Misleading

Three scenarios produce false negatives. First, patients who have already reduced or eliminated gluten before testing may have antibody levels fall below detection. A 2015 study in Alimentary Pharmacology and Therapeutics found that 6 to 8 weeks of a low-gluten diet could normalize tTG-IgA even in biopsy-confirmed celiac patients. Second, IgA-deficient patients test negative on all IgA-based markers while potentially still having active disease, detectable only via DGP-IgG or HLA typing. Third, early or mild disease with minimal mucosal involvement may not yet generate detectable antibody levels.

If a patient has persistent symptoms, iron-deficiency anemia unexplained by other causes, unexplained B12 or folate deficiency, or a strong family history, a negative panel should prompt repeat testing after confirmed gluten exposure for at least 6 to 8 weeks (a gluten challenge), HLA-DQ2/DQ8 genotyping, or direct duodenal biopsy. HLA typing is particularly useful here because the absence of HLA-DQ2 and HLA-DQ8 makes celiac disease biologically improbable, with a negative predictive value exceeding 99%.

Celiac Disease Overlap with Iron Deficiency, B12 Deficiency, and Hypothyroidism

This overlap is where the celiac panel becomes most relevant to a HealthRX audience, because patients presenting with unexplained fatigue, hair loss, cold intolerance, or slow metabolism are often evaluated for thyroid dysfunction first and celiac disease second, or not at all.

Iron and Ferritin

Iron-deficiency anemia is the most common extraintestinal presentation of celiac disease in adults, sometimes appearing years before gastrointestinal symptoms. A study in the American Journal of Gastroenterology (N=672) found that 46% of newly diagnosed celiac patients had iron deficiency. The proximal duodenum, the site of maximal iron absorption, is also the site of the earliest and most severe mucosal damage in celiac disease. When iron replacement therapy fails to correct anemia despite adequate oral dosing, celiac disease should be in the differential.

B12 and Folate

Folate is absorbed in the proximal small intestine; B12 requires intact terminal ileum function. Both can be impaired in extensive celiac disease. Deficiency of either produces macrocytic anemia and, for B12, potential neurological manifestations including peripheral neuropathy. Correcting the diet without addressing the deficiency, or addressing the deficiency without correcting the diet, produces incomplete recovery.

Hashimoto's Thyroiditis and Hypothyroidism

Celiac disease and autoimmune thyroid disease share the HLA-DQ2 genetic background and co-occur at rates significantly above population prevalence. A meta-analysis published in the Journal of Clinical Endocrinology and Metabolism (2017) found the prevalence of autoimmune thyroid disease in celiac patients to be approximately 19.4%, versus roughly 6 to 8% in the general population. Clinically, some patients on stable levothyroxine doses find their TSH rises after untreated celiac disease is diagnosed and normalized, because levothyroxine absorption depends on intestinal integrity. Starting a gluten-free diet can reduce the levothyroxine dose needed to maintain euthyroidism in this subset.

A practical clinical decision framework for patients with both abnormal thyroid labs and unexplained anemia:

1. Order TSH, free T4, tTG-IgA, total IgA, CBC, serum ferritin, and B12 simultaneously in the initial workup.
2. If tTG-IgA is positive at any level, confirm with EMA-IgA before attributing symptoms to thyroid dysfunction alone.
3. If both thyroid and celiac panels are abnormal, treat celiac disease first with GFD and recheck thyroid function at 6 months before adjusting levothyroxine dose.
4. If tTG-IgA is negative but IgA is low (<7 mg/dL), reorder celiac serology using DGP-IgG and consider HLA typing.

How to Interpret a Celiac Panel When You Are Already on a Gluten-Free Diet

Patients who have modified their diet before testing present a specific interpretive challenge. Antibody levels can fall substantially within weeks of reducing gluten exposure. A negative or low result in this context does not exclude celiac disease.

The Gluten Challenge Protocol

To restore diagnostic accuracy, a gluten challenge is required before repeat serology or biopsy. ACG 2023 guidelines recommend consuming at least 3 grams of gluten per day (roughly two slices of wheat bread) for a minimum of 2 weeks before biopsy and 6 to 8 weeks before serology. Some patients cannot tolerate this due to severe symptoms. For those individuals, HLA-DQ2/DQ8 typing is a reasonable alternative first step because negative HLA effectively rules out the disease without requiring gluten re-exposure.

Monitoring Antibody Trends on the Gluten-Free Diet

Once a diagnosis is established and the GFD is started, repeat tTG-IgA at 6 months and 12 months. A 2011 study in Alimentary Pharmacology and Therapeutics (N=465) found that in adherent patients, tTG-IgA normalized (fell below ULN) in 66% of adults by 12 months and 90% by 24 months. Persistent elevation at 12 months despite reported dietary adherence indicates ongoing gluten exposure, either intentional, inadvertent, or from cross-contamination, and warrants dietitian review and possible repeat biopsy.

Antibody normalization tracks, but does not perfectly mirror, mucosal healing. Histologic recovery in adults lags behind serologic recovery by months to years in many cases.

How Celiac Panel Results Change Specific Treatment Decisions

The numeric result is not just a binary positive/negative. The level, trajectory, and context of your celiac panel values shape treatment decisions in concrete ways.

Decision 1: Biopsy or No Biopsy

• tTG-IgA <1× ULN with adequate IgA: no biopsy indicated unless high clinical suspicion persists.
• tTG-IgA 1 to 10× ULN: biopsy recommended before initiating GFD in adults.
• tTG-IgA ≥10× ULN with positive EMA-IgA: biopsy may be bypassed in children (ESPGHAN 2020); increasingly accepted in symptomatic adults with ACG 2023 guidance.

Decision 2: Supplementation Protocol

Nutrient deficiencies at diagnosis drive an individualized supplementation plan. Patients with tTG-IgA above 10× ULN tend to have more severe villous atrophy and deeper deficits. A reasonable starting protocol for confirmed celiac disease with moderate-to-severe mucosal damage includes:

• Iron: 150 to 200 mg elemental iron daily in divided doses until ferritin exceeds 30 ng/mL.
• Folate: 1 mg daily for at least 3 to 6 months.
• Vitamin B12: 1,000 mcg intramuscularly monthly for 3 months if serum B12 is below 200 pg/mL, then transition to oral supplementation if absorption has recovered.
• Vitamin D: 2,000 to 4,000 IU daily based on 25-OH vitamin D level, with a target above 30 ng/mL.

Supplementation continues until serology normalizes and repeat labs confirm repletion. Oral supplementation may remain insufficient if mucosal healing is slow, requiring parenteral alternatives.

Decision 3: Medication Absorption Adjustments

As mentioned in the thyroid overlap section, levothyroxine dose may need downward adjustment as the gut heals. A prospective study in Thyroid (2012, N=34) found that a significant subset of hypothyroid patients with celiac disease required lower levothyroxine doses after 12 to 24 months on a strict GFD, with a mean dose reduction of approximately 17%. Similar absorption-dependent medications, including oral bisphosphonates, certain anticonvulsants, and some hormonal therapies, may also require dose review at 6-month intervals during mucosal recovery.

Decision 4: Screening First-Degree Relatives

A positive celiac panel in one family member changes the management of their relatives. The ACG and American Gastroenterological Association both recommend offering serologic screening to first-degree relatives of confirmed celiac patients. The lifetime risk of celiac disease in first-degree relatives is approximately 10%, compared to roughly 0.7 to 1.4% in the general population. Identifying relatives early, before symptom onset, can prevent years of nutrient depletion and associated complications including osteoporosis and peripheral neuropathy.

Refractory Celiac Disease: When Numbers Stay High Despite the Diet

A small subset of celiac patients, estimated at 1 to 2% of diagnosed cases, fail to respond serologically or histologically to a strict GFD after 12 to 24 months. This is classified as refractory celiac disease (RCD) and requires specialist evaluation. A 2021 review in the World Journal of Gastroenterology distinguishes two subtypes: RCD type I (normal intraepithelial lymphocyte phenotype, better prognosis) and RCD type II (aberrant lymphocyte clone, risk of progression to enteropathy-associated T-cell lymphoma). Persistent tTG-IgA elevation beyond 24 months of confirmed GFD adherence should trigger referral to a gastroenterologist with celiac subspecialty experience, repeat biopsy with flow cytometry, and consideration of immunosuppressive therapy such as budesonide or, in RCD type II, cladribine.